SCHEDULE 13G/A: BlackRock Discloses 6.8% Stake in Neurogene Inc. Common Stock

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 6.8% beneficial ownership stake in Neurogene Inc.'s common stock as of March 31, 2025.

Summary

• BlackRock, Inc. reported beneficial ownership of 1,011,436 shares of Neurogene Inc. common stock.
• This ownership represents 6.8% of Neurogene Inc.'s total outstanding common stock.
• BlackRock holds sole voting power over 999,743 shares and sole dispositive power over 1,011,436 shares.
• The filing is an Amendment No. 1 to a previous Schedule 13G, indicating an update to their prior disclosure.
• BlackRock certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Neurogene Inc.
• Several BlackRock subsidiaries, including BlackRock Advisors, LLC and BlackRock Fund Advisors, are identified as entities through which the ownership is held, with at least one beneficially owning 5% or greater of the outstanding shares.

Sentiment

Score: 5

Explanation: The document is a factual, routine regulatory filing disclosing beneficial ownership. It contains no positive or negative sentiment regarding the issuer's performance or outlook, nor does it imply any strategic shift by the reporting entity.

Future Outlook

No forward-looking statements or guidance regarding Neurogene Inc.'s performance or BlackRock's future investment strategy are provided in this beneficial ownership disclosure.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11."

Industry Context

This filing represents a routine disclosure by BlackRock, a major institutional asset manager, regarding its passive investment stake in Neurogene Inc. Such Schedule 13G filings are standard for large investment firms that cross the 5% beneficial ownership threshold in publicly traded companies, indicating a passive investment intent rather than an activist one.

Stakeholder Impact

• Shareholders of Neurogene Inc. gain transparency into the significant institutional ownership by BlackRock, which can be viewed as a vote of confidence in the company by a major asset manager.
• The disclosure confirms BlackRock's passive investment intent, indicating no immediate plans to influence company control, which may reassure existing management and other shareholders.

Key Dates

Keywords

Neurogene Inc., BlackRock Inc., Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, NROGN, Investment Management